Company Profile
Pacira BioSciences Stock Price, News & Analysis
- Ticker:
- PCRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
25.58 USD (+2.85%)
Close
Last updated: August 6, 2026
875M USD
Market cap
Why the stock is moving
The latest monitored company update is “Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Non-Opioid Pain Management
Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program.
EXPAREL
EXPAREL is a multivesicular-liposome formulation of bupivacaine that provides prolonged local or regional analgesia after surgery. It is approved for infiltration and selected nerve blocks and anchors Pacira’s commercial franchise.
ZILRETTA
ZILRETTA is an extended-release intra-articular corticosteroid approved for osteoarthritis knee pain. A completed-enrollment Phase 3 study is evaluating expansion into osteoarthritis pain of the shoulder.
Iovera
Iovera is a handheld device that applies controlled cold temperatures to targeted nerves for immediate, drug-free pain relief. Pacira is also pursuing a registrational indication in spasticity.
PCRX-201
PCRX-201, or enekinragene inzadenovec, is a locally administered gene therapy in Phase 2 development for knee osteoarthritis. It uses a high-capacity adenoviral platform intended to drive local therapeutic protein expression with commercially viable manufacturing.
Future catalysts
Part A Phase 2 data for PCRX-201 in knee osteoarthritis expected in 2026.
Topline results from the Phase 3 ZILRETTA shoulder-osteoarthritis study expected by year-end 2026.
Registrational iovera spasticity-study results expected in 2026.
Recent news
- 01
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Pacira BioSciences
- 02
- 03
Pacira BioSciences Reports Second Quarter 2026 Financial Results
Source: Pacira BioSciences
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pacira BioSciences (PCRX)?
Pacira BioSciences (PCRX) most recently closed at 25.58 USD, a +2.85% move versus the previous session.
What is the market cap of Pacira BioSciences (PCRX)?
Pacira BioSciences currently has a market capitalization of 875M USD on BioPharmSignal.
What does Pacira BioSciences do?
Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program. EXPAREL EXPAREL is a multivesicular-liposome formulation of bupivacaine that provides...
On which exchange is PCRX stock listed?
Pacira BioSciences (PCRX) is associated with NASDAQ, United States, Biopharma.
What is PCRX-201?
Part A Phase 2 data for PCRX-201 in knee osteoarthritis expected in 2026.
Which conditions is Pacira BioSciences targeting with PCRX-201?
Part A Phase 2 data for PCRX-201 in knee osteoarthritis expected in 2026.
How does Pacira BioSciences describe recent progress with PCRX-201?
Part A Phase 2 data for PCRX-201 in knee osteoarthritis expected in 2026.
What is Non-Opioid?
Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain.